- Home
- CPBI vs IFRX Comparison
CPBI vs IFRX Comparison
Compare CPBI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CPBI | IFRX |
|---|---|---|
| Founded | 2023 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 60.6M |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CPBI | IFRX |
|---|---|---|
| Price | $17.57 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 4.6K | ★ 171.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.00 | $0.71 |
| 52 Week High | $17.87 | $1.94 |
Technical Indicators
Market Signals| Indicator | CPBI | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 52.69 |
| Support Level | $17.37 | $0.75 |
| Resistance Level | $17.87 | $1.16 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 61.33 | 50.85 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.